• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺动脉高压:流行病学和注册研究。

Pulmonary arterial hypertension: epidemiology and registries.

机构信息

Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.

Division of Cardiovascular Diseases, Allegheny General Hospital, Pittsburgh, Pennsylvania.

出版信息

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D51-9. doi: 10.1016/j.jacc.2013.10.023.

DOI:10.1016/j.jacc.2013.10.023
PMID:24355642
Abstract

Registries of patients with pulmonary arterial hypertension (PAH) have been instrumental in characterizing the presentation and natural history of the disease and provide a basis for prognostication. Since the initial accumulation of data conducted in the 1980s, subsequent registry databases have yielded information about the demographic factors, treatment, and survival of patients and have permitted comparisons between populations in different eras and environments. Inclusion of patients with all subtypes of PAH has also allowed comparisons of these subpopulations. We describe herein the basic methodology by which PAH registries have been conducted, review key insights provided by registries, summarize issues related to interpretation and comparison of the results, and discuss the utility of data to predict survival outcomes. Potential sources of bias, particularly related to the inclusion of incident and/or prevalent patients and missing data, are addressed. A fundamental observation of current registries is that survival in the modern treatment era has improved compared with that observed previously and that outcomes among PAH subpopulations vary substantially. Continuing systematic clinical surveillance of PAH will be important as treatment evolves and as understanding of mechanisms advance. Considerations for future directions of registry studies include enrollment of a broader population of patients with pulmonary hypertension of all clinical types and severity and continued globalization and collaboration of registry databases.

摘要

肺高血压(PAH)患者的登记研究在描述疾病的表现和自然史以及提供预后基础方面发挥了重要作用。自 20 世纪 80 年代首次积累数据以来,随后的登记数据库提供了有关人口统计学因素、治疗和患者生存的数据,并允许在不同时代和环境的人群之间进行比较。包括所有 PAH 亚型的患者也允许对这些亚人群进行比较。本文描述了 PAH 登记研究的基本方法,回顾了登记研究提供的关键见解,总结了与解释和比较结果相关的问题,并讨论了数据预测生存结果的实用性。还讨论了潜在的偏倚来源,特别是与包括新发病例和/或现患病例以及数据缺失相关的偏倚。当前登记研究的一个基本观察结果是,与以前观察到的情况相比,在现代治疗时代,PAH 的生存率有所提高,并且 PAH 亚人群的结局差异很大。随着治疗的发展和对机制的理解的提高,对 PAH 的持续系统临床监测将非常重要。未来登记研究的方向包括招募更广泛的各类临床严重程度的肺动脉高压患者,并继续进行登记数据库的全球化和协作。

相似文献

1
Pulmonary arterial hypertension: epidemiology and registries.肺动脉高压:流行病学和注册研究。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D51-9. doi: 10.1016/j.jacc.2013.10.023.
2
[Pulmonary arterial hypertension: epidemiology and registries].肺动脉高压:流行病学与登记处
Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:67-77.
3
Definition, epidemiology and registries of pulmonary hypertension.肺动脉高压的定义、流行病学及登记系统
Heart Fail Rev. 2016 May;21(3):223-8. doi: 10.1007/s10741-015-9510-y.
4
Survival in pulmonary hypertension in Spain: insights from the Spanish registry.西班牙肺动脉高压患者的生存状况:来自西班牙注册研究的观察。
Eur Respir J. 2012 Sep;40(3):596-603. doi: 10.1183/09031936.00101211. Epub 2012 Feb 23.
5
Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries.肺动脉高压预后工具的开发:来自现代登记处的经验教训。
Thromb Haemost. 2012 Dec;108(6):1049-60. doi: 10.1160/TH11-11-0821. Epub 2012 Sep 5.
6
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.美国肺动脉高压患者的变化情况:REVEAL 与历史和非美国当代注册研究的不同之处。
Chest. 2011 Jan;139(1):128-37. doi: 10.1378/chest.10-0075. Epub 2010 Jun 17.
7
Long-term data from the Swiss pulmonary hypertension registry.来自瑞士肺动脉高压注册中心的长期数据。
Respiration. 2015;89(2):127-40. doi: 10.1159/000370125. Epub 2015 Jan 31.
8
Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management.儿童肺动脉高压的生存状况:来自登记处评估早期和长期肺动脉高压疾病管理的见解。
Circulation. 2012 Jan 3;125(1):113-22. doi: 10.1161/CIRCULATIONAHA.111.026591. Epub 2011 Nov 15.
9
Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.重度特发性、遗传性或食欲抑制剂相关性肺动脉高压患者目前使用依前列醇的情况:来自法国肺动脉高压注册研究的数据
Int J Cardiol. 2014 Apr 1;172(3):561-7. doi: 10.1016/j.ijcard.2013.12.313. Epub 2014 Jan 22.
10
Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis.肺动脉高压患者的合并症和结局:REVEAL 登记分析。
Chest. 2013 Jul;144(1):169-176. doi: 10.1378/chest.11-3241.

引用本文的文献

1
Dissecting contributions of pulmonary arterial remodeling to right ventricular afterload in pulmonary hypertension.剖析肺动脉重塑对肺动脉高压患者右心室后负荷的影响。
Bioeng Transl Med. 2025 Jun 26;10(4):e70035. doi: 10.1002/btm2.70035. eCollection 2025 Jul.
2
Pulmonary arterial hypertension with cardiopulmonary comorbidities: is it a unique phenotype?合并心肺疾病的肺动脉高压:它是一种独特的表型吗?
BMC Pulm Med. 2025 Jul 22;25(1):348. doi: 10.1186/s12890-025-03833-4.
3
Pulmonary arterial hypertension treatment. A new era.肺动脉高压治疗。一个新时代。
Int J Cardiol Congenit Heart Dis. 2025 May 27;21:100594. doi: 10.1016/j.ijcchd.2025.100594. eCollection 2025 Sep.
4
Global, regional, and national trends in pulmonary arterial hypertension burden, 1990-2021: findings from the global burden of disease study 2021.1990-2021年肺动脉高压负担的全球、区域和国家趋势:全球疾病负担研究2021的结果
Front Public Health. 2025 May 29;13:1516365. doi: 10.3389/fpubh.2025.1516365. eCollection 2025.
5
Physiologic relevance of the transpulmonary metabolome in connective tissue disease-associated pulmonary vascular disease.经肺代谢组在结缔组织病相关肺血管疾病中的生理相关性
JCI Insight. 2025 May 8;10(9). doi: 10.1172/jci.insight.187911.
6
Morbidity and Mortality Associated With Pulmonary Arterial Hypertension in a Schistosomiasis-Endemic Region of Brazil.巴西血吸虫病流行地区肺动脉高压相关的发病率和死亡率
Pulm Circ. 2025 Apr 27;15(2):e70086. doi: 10.1002/pul2.70086. eCollection 2025 Apr.
7
The Challenge in Burden of Pulmonary Arterial Hypertension: A Perspective From the Global Burden of Disease Study.肺动脉高压负担面临的挑战:来自全球疾病负担研究的视角
MedComm (2020). 2025 Apr 24;6(5):e70175. doi: 10.1002/mco2.70175. eCollection 2025 May.
8
Risk Factors for Adverse Outcomes in Connective Tissue Disease-Associated Pulmonary Hypertension.结缔组织病相关肺动脉高压不良结局的危险因素
Rev Cardiovasc Med. 2025 Mar 17;26(3):26877. doi: 10.31083/RCM26877. eCollection 2025 Mar.
9
Pregnancy and pulmonary artery hypertension: Management challenges.妊娠与肺动脉高压:管理挑战
Int J Cardiol Congenit Heart Dis. 2025 Jan 7;19:100566. doi: 10.1016/j.ijcchd.2025.100566. eCollection 2025 Mar.
10
The Pulmonary Artery Pulsatility Index Provides No Additional Prognostic Information in Pediatric Pulmonary Arterial Hypertension.肺动脉搏动指数在小儿肺动脉高压中未提供额外的预后信息。
Children (Basel). 2024 Sep 24;11(10):1152. doi: 10.3390/children11101152.